Sales Of Drug-Spiked Supplements After Warnings Show Stronger US Regulation Needed – Study
Executive Summary
"FDA should consider ways to ensure that prohibited drugs are removed from supplements, perhaps by testing products sold after warning letters and mandating recalls whenever products remain adulterated,” say Pieter Cohen and colleagues in JAMA study.
You may also be interested in...
QR Access Launched For US FDA’s ‘High-Risk’ Supplements, Other Compliance Concerns
QR codes provided to reach FDA website pages with information supplement firms frequently need. As well as ingredients in supplements of concern to agency, compliance program pages identify products considered high-risk, a list including supplements with NDIs and are available in multiple dosage forms.
With Mandatory Product Listing, FDA Not Looking For Gate To Open Or Close On Supplements
Mandatory product listings would help FDA eliminate gap of missing NDI notifications it expects haven't been filed and other information about ingredients but not establish pre-market approval tool.
Senate FDA User Fee Bill’s Mandatory Supplement Listing Provision Unites Industry In Opposition
Senate HELP Committee didn’t add amendments to user fee bill to protect confidential information and prevent FDA over-regulation in an MPL program, trade groups say. MPL proponents join opponents in saying language in S.4348 isn’t the answer.